Discover Healthy Tips with NKX019 for Lupus Nephritis

Clinical Trial of NKX019 for Lupus Nephritis Begins

A multi - center Clinical trial known as Ntrust-1 is currently underway to investigate the effectiveness of NKX019 , a Cell therapy , in treating lupus nephritis ( LN ) , which is a form of lupus - related kidney disease . The study aims to enroll up to 12 participants with refractory LN who will undergo the cell therapy on Days 0 , 7 , and 14 of the trial . Some participants may even receive additional treatment cycles to enhance their response.

NKX019 is a type of chimeric antigen receptor natural killer ( CAR NK ) cell therapy that specifically targets CD19 positive B cells . These natural killer ( NK ) cells are a type of lymphocyte that play a crucial role in destroying infected and diseased cells in the body . NKX019 is created by isolating NK cells from healthy donor blood and then modifying them with a CAR that is designed to recognize and attack CD19 , a protein present on the surface of B cells.

New Clinical Trial Approved for Autoimmune Diseases

In addition to the Ntrust-1 trial , the Food & Drug Administration has also given approval for a second open - label , multi - center clinical trial , known as Ntrust-2 , to study the efficacy of NKX019 in treating systemic sclerosis , myositis , and vasculitis , which are Autoimmune diseases . Both trials will evaluate the safety of NKX019 in individuals with autoimmune diseases and its potential to induce long - term remission by resetting the immune system through the elimination of pathogenic B cells.

Clinical data from both the Ntrust-1 and Ntrust-2 trials is anticipated to be available in 2025 . It is recommended to stay informed by following updates from the Lupus Foundation of America regarding advancements in lupus treatments and ongoing clinical trials . Stay informed about the latest developments in treatments being researched for lupus to stay updated on potential breakthroughs.

By participating in these clinical trials and staying informed about the progress of NKX019 , individuals living with lupus and other autoimmune diseases can potentially benefit from novel cell therapies and advancements in gene therapy to manage their conditions effectively.